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Summary
Objectives: Prednisolone and thalidomide are commonly used in the management
of erythema nodosum leprosum (ENL) and bring relief to patients with this condition
worldwide. However, both ENL and its treatments can cause significant morbidity.
This study describes the spectrum of ENL seen at The Hospital for Tropical Diseases,
London (HTD), the use of steroids and thalidomide in its management and the
complications of their use.
Study Design: We conducted a retrospective audit of patients diagnosed with ENL
between 1996 and 2013. Data were obtained from hospital records including severity
and length of disease, together with treatments received and adverse effects.
Results: Between 1996 and 2013, 30 patients were diagnosed with ENL. The
median bacillary index (BI) at diagnosis was 4·65, higher than in previous studies.
Most patients developed ENL during leprosy treatment (67%) and had chronic ENL
(57%). The median length of ENL was 60 months (range 9–192); patients with
BI . 4·5 had significantly longer duration of disease. 87% patients received
prednisolone for median nine months; 35% developed adverse effects including
diabetes and hypertension. 87% patients received thalidomide for median 16 months;
65% complained of side effects. There were no pregnancies or venous
thromboembolisms. 77% patients stopped prednisolone within two months of
starting thalidomide. There were no deaths in our cohort.
Conclusion: We describe the clinical course of ENL in a non-endemic country with
access to thalidomide and prednisolone. ENL may last far longer than previously
described and has significant impact on a patient’s health. In the UK, thalidomide is
essential as a steroid-sparing agent, to prevent the adverse effects and mortality of
long-term steroids which have been documented elsewhere.
Correspondence to: Laura Nabarro, The Hospital for Tropical Diseases, Mortimer Market, Capper Street,
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Introduction
ENL is a multisystem, relapsing and remitting disorder occurring in patients with
lepromatous and borderline lepromatous leprosy. Although its pathogenesis is not fully
understood, it is characterized by immune complex deposition and T cell activation with high
levels of TNFa and IL6.1 This manifests clinically as tender erythematous skin lesions with
or without systemic symptoms such as fever, neuritis, orchitis and bone pain. The incidence
of ENL varies from 5%2 to 49%3 in cohorts worldwide. Risk factors include having
lepromatous leprosy or a bacillary index (BI) over 4.3
The management of ENL is difficult. Anti-inflammatory agents are rarely sufficient for
symptomatic control. Prednisolone rapidly controls symptoms but risks the complications of
long-term steroid treatment.4 Thalidomide is effective but associated with side effects
including tiredness, constipation and neuropathy. It is unavailable in many countries due to
concern about teratogenic risk.5 Clofazimine can be effective as an anti-inflammatory agent
at a dose of 300mg/day. However, it takes four weeks to work and the associated skin
pigmentation can be stigmatizing for patients in leprosy endemic areas.6
Other disease modifying agents have been tried with varying success. Case reports7,8 and
a small case series suggest azathioprine may reduce the frequency and severity of ENL
episodes and may be effective as a steroid sparing agent.9 Both etanercept and infliximab,
tumour necrosis factor- alpha (TNFa) inhibitors, have been reported to be effective in
individual patients with severe ENL.10,11 The utility and safety of expensive
immunosuppressive agents in resource poor settings where tuberculosis is endemic has yet
to be established.
The Hospital for Tropical Diseases, London, (HTD) is a tertiary centre for tropical disease
and runs the leprosy referral clinic for the UK National Health Service. The majority of
patients diagnosed with leprosy in the UK are referred to this clinic. Most patients receive the
WHO recommended multidrug therapy (MDT) of rifampicin, clofazimine and dapsone in
blister packs provided by WHO. Patients who have adverse effects to first line treatment are
given alternative regimens, such as monthly rifampicin, ofloxacin and minocycline (ROM).
Prednisolone, clofazimine and azathioprine are available for the management of ENL.
Thalidomide is prescribed through the System for Thalidomide Education and Prescribing
Safety (S.T.E.P.S.). TNFa inhibitors are not currently available for patients with ENL.
This retrospective case note review aims to describe the spectrum of ENL seen at HTD,
the use of steroids and thalidomide in its management and the complications of their use.
Although this manuscript describes the side effects of drugs used in ENL treatment, we
emphasise that these drugs bring relief to ENL patients worldwide.
Method
We conducted a retrospective audit of the management of patients with ENL seen at the
Hospital for Tropical Diseases, London, between January 1996 and December 2013. Ethical
approval was not required as this was an audit of our current practice.
Data were obtained from hospital records including case notes from consultations and in-
patient admissions, electronic letters and laboratory records. Data collected included age, sex,
country of origin, country where leprosy was acquired, Ridley-Jopling classification, BI at
diagnosis, treatment regimen, treatment length and occurrence of ENL. Further data were
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collected about ENL including timing, pattern, severity and length of disease together with
treatments used.
Adverse effects of steroids were recorded including weight gain, diabetes, hypertension,
osteoporosis, cataracts and occurrence of infections. Adverse effects of thalidomide were also
recorded including tiredness, constipation, dizziness, abdominal pain, unplanned pregnancy
and venous thromboembolism. The neurological outcomes of thalidomide treatment are
currently being collected and will be reported separately. As these data were collected
retrospectively from notes, letters and laboratory records rather than from systematic patient
interview, the occurrence of adverse events may be underestimated.
Table 1 details the case definitions used.
Results
Between 1996 and 2014, 18 patients with BL and 46 patients with LL were seen at HTD. Four
(22%) patients with BL and 26 (56%) patients with LL developed ENL.
Table 1. Case definitions. Type and severity of ENL have been adapted from previous studies looking at the clinical
course of ENL in Ethiopia2 and India18.
Case Definitions
Reactions Erythema nodosum leprosum The presence of tender skin nodules with or without
other systemic symptoms
Type of ENL2 Acute Episode of ENL lasting less than 6 months in which
treatment was slowly withdrawn with no recurrence
of ENL whilst on treatment
Recurrent At least one further episode of ENL occurring 28 days
or more after withdrawal of treatment for ENL
Chronic Episode of ENL lasting longer than 6 months during
which patient is on continuous ENL treatment or any
treatment free periods are less than 28 days.
Severity of ENL18 Mild A few mildly tender lesions with or without mild aches
and pain or low grade fevers without neuritis
Moderate Mild ENL with neuritis or with more than three systemic
symptoms such as joint pain, bone pain, anorexia,
malaise, lymphadenopathy
Severe Multiple skin nodules with high grade fever and organ
involvement (iritis, orchitis, severe neuritis)
Onset of ENL Before MDT History of ENL onset before MDT was started or
presence of ENL when MDT was started
During MDT ENL which started during MDT
After MDT ENL which started after MDT had finished
ENL treatment High dose clofazimine More than 50mg per day of clofazimine OR clofazimine
prescribed independently of MDT.
Self-directed therapy Rescue packs of prednisolone or thalidomide kept by the
patient and taken in short course when the patient
experienced a flare-up of ENL.
Duration of ENL treatment Time from initial ENL symptoms until termination of
symptoms OR the patient stopped taking treatment
for ENL (whichever was latest)
Complications of steroid use Hypertension, steroid induced diabetes, cataracts,
osteoporosis, weight gain, infection
Complications of thalidomide use Tiredness, constipation, unplanned pregnancy,
dizziness, abdominal pain, venous thromboembolism
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Of 30 patients with ENL, 20 (67%) were male. Ten (33%) patients acquired leprosy in
South Asia, ten (33%) in South America and seven (23%) in West Africa. The median age at
leprosy diagnosis was 33 years; 29 (97%) patients were of working age and 24 (80%) were
between 20 and 40 years old. Patients had a median of 18 months of symptoms before the
diagnosis of leprosy was made. The median BI at diagnosis was 4·65 (4·7 in patients with LL
and 2·6 in patients with BL leprosy). Twenty-two (73%) patients had a BI over 4. All patients
received multi-drug therapy (see Figure 1).
Nine (30%) patients developed ENL before starting leprosy treatment, 20 (67%) during
treatment and one (3%) after treatment. Thirteen (43%) patients had recurrent ENL and
17 (57%) patients had chronic ENL. No patients had acute ENL.
The median length of ENL was 60 months (range: 9 to 192 months). Four (13%) patients
had ENL for more than 10 years (see Figure 2).
Those with an initial BI over 4·5 had a median length of ENL of 76 months in comparison
to 40 months in patients with a BI of 4·5 or less (Mann Whitney u test, P 0·043). Sixteen
(53%) patients had moderate disease with four (13%) experiencing severe disease. There
were no deaths in this cohort.
30 patients
28 received rifampicin,
clofazimine and dapsone.
22 completed therapy
6 changed regimenc
3 received rifampicin,
ofloxacin and minocycline
1 received rifampicin,
ofloxacin, minocycline and
clofazimine
1 received rifampicin and
clofazimine
1 received
rifampicin,
dapsone, ofloxacin
1 received rifampicin,
ofloxacin and minocyclinea
1 received rifampicin and
dapsoneb
aThis patient had previously been partially treated in India but had developed severe
clofazimine pigmentation hence was started on a clofazimine free regimen.
bThis patient received rifampicin and dapsone alone as treatment had been started
elsewhere and the BI was low.
c6 (20%) patients changed regimen due to complications of therapy; 5 due to severe
clofazimine pigmentation and one to enable directly observed treatment with the ROM regimen.
dThe median duration of treatment is longer than advised by the WHO as patients with a
BI≥4 are treated for 2 years or until their BI falls below 2, due to the higher rate of
relapse in these patients.
Median length of treatment 30 monthsd
Figure 1. Treatment regimens of patients with ENL.
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Twenty six (87%) patients received prednisolone, 26 (87%) received thalidomide, five
(17%) received high dose clofazimine and four (13%) received a further disease modifying
agent. Figure 3 shows the combinations of treatments that patients received.
Prednisolone was given for a median of 9 months (range 1 week to 74 months) at a dose
range of 5mg to 80mg/day. The median maximum dose of prednisolone was 40mg/day;
patients were initially started at this dose and the dose was then reduced as their ENL was
controlled. Of note, three (11%) patients were already on prednisolone for neuritis or Type 1
reaction when they developed symptoms of ENL. Nine (35%) patients developed side effects
whilst on treatment; seven (27%) gained weight, four (15%) developed Cushingoid features
and three (11%) developed steroid-induced diabetes. One patient developed a Listeria
monocytogenes meningitis which was attributed to steroid use. Six (23%) had self-directed
treatment at the end of therapy; these patients kept rescue packs of prednisolone at home and
took a short course if they experienced an ENL flare-up.
Thalidomide was given for a median of 16 months (range 2 weeks to 175 months) at a
dose range of 12.5mg to 500mg/day. The median maximum dose of thalidomide was 400mg
0 50 100 150 200 250
1
4
7
10
13
16
19
22
25
28
Time (months)
Pa
tie
nt
Median 60 months
Range 9–192 months
BI>4·5: median length 76 months
BI<4·5: median length 40 months (P 0·0043)
Figure 2. Duration of ENL.
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Figure 3. Combinations of treatments that patients received.
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per day. Twenty (77%) patients were on prednisolone when thalidomide was started.
The median time from developing ENL to starting thalidomide was 5 months in men and 8
months in women. Twenty (77%) were weaned off prednisolone whilst taking thalidomide in
a median of 2 months. Seventeen (65%) patients had side effects on thalidomide: 16 (61%)
felt tired, four (15%) felt dizziness and four (15%) complained of constipation. There were no
unplanned pregnancies or venous thromboembolisms.
Ten women received thalidomide. Two of these women were post-menopausal and
thus did not require contraception. Of seven patients whose contraception was documented,
six (86%) used condoms, four (57%) used the oral contraceptive pill, three (43%) used a coil
and one (14%) used the Depo contraceptive injection. One patient was documented to be
using contraception but the type was not recorded in the patient’s records. Of five women
who received thalidomide after the introduction of the S.T.E.P.S. programme, all had a
negative pregnancy test documented at over 90% of appointments at which thalidomide
was prescribed.
Four patients received clofazimine at doses between 100mg and 300mg per day. Three
patients received azathioprine for between 8 and 44 months at a dose between 200mg and
300mg per day. These three patients had ENL of moderate severity that was not controlled on
40mg prednisolone per day. In the first patient, introduction of azathioprine allowed a
reduction in prednisolone to 10mg per day at 2 months but the patient continued to require
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Figure 4. The clinical course of a patient with ENL, type 1 reaction and neuritis. The patient was treated with
prednisolone and thalidomide and developed steroid induced diabetes and hypertension as a complication of
treatment.
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2·5–10mg prednisolone daily for a further 22 months before prednisolone could be stopped
permanently. In the second patient, prednisolone was reduced to less than 10mg per day at
11 months and then stopped completely at 23 months. The third patient did not respond to
8 months of azathioprine and required increased doses of prednisolone to control the
symptoms of ENL.
The median length of follow up after ENL had terminated was 29 months (range 1–144
months). In 10 patients for whom electronic documentation of outpatient appointments was
available, the median number of attended appointments was 49.
Figures 4 and 5 show the clinical course of two patients with ENL.
Discussion
This is the first study to describe the clinical course of ENL in a clinic where patients can be
treated with thalidomide and prednisolone in a non-endemic region.
Compared to other cohorts, the rate of ENL in our study is high: 56% of our patients with
LL leprosy developed ENL compared to 49% of LL patients in a hospital-based study with
similar inclusion criteria and case definitions in Hyderabad, India.3 Other studies have found
lower rates of ENL; 31% in multibacillary patients in Brazil12 and 5% in field studies of
multibacillary patients in Ethiopia. The differing inclusion criteria, case definitions and
clinical settings may account for the variation between studies.13 However, the median BI at
diagnosis in our cohort was 4·65 compared to 3·5 in Hyderabad;3 63% of our patients had over
12 months of symptoms before being diagnosed with leprosy compared to 52% of patients in
Nepal.14 We postulate that delay in diagnosis may result in a higher BI and, as a high BI is a
known risk factor for ENL,3 increased rates of ENL in our cohort. The UK is a non-endemic
area with an average of 10 new leprosy diagnoses per year. Awareness of leprosy is low
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Figure 5. The clinical course of a patient with chronic severe ENL maintained on thalidomide with intermittent
prednisolone.
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outside the specialties of dermatology, infectious disease and neurology. This may contribute
to delays in diagnosis.
As in previous studies3,14 most of our patients developed ENL whilst on leprosy
treatment. However, our patients had a longer duration of ENL (median 60 months, range
9-192 months) than previously reported. In Hyderabad, the median duration of ENL was 18·5
months.3 In Nepal, the range was 1 to 62 months. The longest case of ENL previously
documented in the literature is 96 months,15 far shorter than our maximum ENL duration of
192 months. Figure 5 shows the clinical course and treatment of a patient with chronic severe
ENL for 105 months.
It is unclear why our cohort has a longer median duration of ENL than previously
recorded but we suspect that it is a combination of three factors. Firstly, it may be due to delay
in leprosy diagnosis; our patients had a higher BI at diagnosis resulting in a longer time to
clear M. leprae antigen from skin, thus a prolonged period of immune complex deposition
causing symptoms of ENL. In our cohort, patients with a BI over 4·5 had a significantly
longer duration of disease than those with a BI of 4·5 or less.
Secondly, there may be some patients with no adverse effects from thalidomide who
received extended courses of treatment because thalidomide kept them symptom free, thus
artificially prolonging the estimated duration of their ENL. Finally, it may be due to the
prolonged follow up of our patients. We reviewed patients for a median 29 months after
their last episode of ENL hence we would expect to identify late recurrences or prolonged
mild ENL. As HTD is the main leprosy clinic in the UK, loss to follow-up is rare and
patients who developed recurrent ENL after discharge would be referred back to our clinic.
Previous studies have not documented duration of follow-up or number of patients lost to
follow-up3,14,15 so may have underestimated the true duration of disease.
The extended duration of ENL has both social and medical implications for patients. Most
of our patients were of child-bearing and working age. In the UK, people whose health is poor
earn 7–15% less and are 34% less likely to be in employment than those in average health.16
In West Bengal, the household cost of ENL was 28% of monthly income and 11% of
households faced catastrophic health expenditure.17
In addition, ENL is often treated with long courses of steroids putting patients at
considerable risk of adverse events; 13% of patients treated with steroids developed steroid-
induced diabetes (SID) compared to 21% and 26% in two studies in India.4,18 The increased
rate may be due to a higher incidence of Type 2 diabetes in South Asia. However, until
recently we did not routinely check patients’ blood sugars or HbA1C, hence our data may
underestimate the true incidence of SID in our cohort. Sugurmaran investigated
complications of steroid therapy in leprosy reactions and found that 23% of patients
developed cataracts and 3% developed TB.4 These complications were not seen in our small
cohort. However, this highlights the importance of systematic recording of side-effects in
patients on steroids, particularly in areas without access to thalidomide. Figure 4 shows the
clinical course and treatment of a patient with ENL and a Type 1 reaction. She developed SID
and hypertension, gained weight and developed a Cushingoid habitus, which she found
particularly distressing.
There were no deaths in our cohort. Walker et al. found a mortality rate of 7·9% in
patients hospitalised for ENL in Ethiopia, where thalidomide is not available. In 50% of
deaths, steroids were identified as a definite contributing factor; these patients died of TB or
septic shock.19 We postulate that the zero mortality in our cohort was due to the availability
of thalidomide.
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Thalidomide allowed 75% of patients to be weaned off steroids in a median of 2 months.
However, it may need to be taken for years and many patients complain of side-effects,
particularly tiredness, which negatively affects their working and social lives. Thalidomide
is prothrombotic; the risk of deep vein thrombosis (DVT) in patients with myeloma on
thalidomide and dexamethasone is 17%20 and there are increasing reports amongst leprosy
patients on thalidomide. None of our patients developed DVT. The occurrence of
thalidomide-induced neuropathy in this cohort is currently being investigated and will be
reported separately.
Eighty percent of female patients were of childbearing age. Use of thalidomide precludes
pregnancy and the S.T.E.P.S. programme mandates that women use two forms of
contraception and attend clinic monthly for pregnancy testing. Although this is effective at
reducing unplanned pregnancy21 it is disruptive to the patient’s working and family life.
Finally, the length of ENL has implications for health care provision. Patients with
ENL attended many outpatient appointments and eight patients required hospital stay. They
received long courses of treatment, some of which resulted in adverse events which
themselves required treatment. As it is impossible to predict the likely length or severity of
ENL at the outset, it is difficult to plan healthcare provision for these patients. Although this
is unlikely to be problematic in the UK where the number of patients with ENL is small,
it may have a significant impact on health care provision in countries where leprosy is
highly endemic.
There were a number of limitations to our study. Notably the small sample size and non-
randomised nature of this study limit the potential to generalise the data to other cohorts of
patients. Most patients received both thalidomide and prednisolone and so it was not possible
to evaluate their individual therapeutic effect. Furthermore, we have not discussed the
neurological toxicity of thalidomide. This will be reported in a separate paper due to the large
amount of data and complexity of this important topic.
As this was a retrospective review of patient records, it was limited by clinical
documentation. In particular, side-effects of treatment were not systematically documented in
notes but only documented if they occurred. Furthermore, our patients did not routinely have
blood sugar, HbA1C and blood pressure measurements performed in clinic and so we may
have underestimated treatment related side-effects.
Conclusion
This study highlights the significant effect that ENL has on patients’ lives even in a developed
country with access to prednisolone, thalidomide and other disease modifying agents. In
particular, it shows that ENL can last far longer than was previously suspected. This has
implications on the working, social and family life of our patients and on health care
provision. It underscores the importance of using thalidomide as a steroid-sparing agent to
prevent adverse events associated with long-term steroid use. Further work is needed to
investigate predictors of ENL severity and length of disease so that patients can be started on
appropriate therapy early on in the illness. In addition, ongoing investigations into effective
steroid-sparing agents in ENL should be supported and further advocacy is needed in leprosy
endemic regions where thalidomide is not available.
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